Condition
Gastroenteritis Norovirus
Total Trials
6
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
6Total
Not Applicable (1)
P 1 (4)
P 2 (1)
Trial Status
Completed4
Withdrawn2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT03395405Phase 2CompletedPrimary
NNITS-Nitazoxanide for Norovirus in Transplant Patients Study
NCT04174560Phase 1CompletedPrimary
Phase I Norovirus Challenge Model
NCT06568380Not ApplicableWithdrawnPrimary
Validation of a Boindicator as Monitoring Tool for Oyster Norovirus Outbreak
NCT02473224Phase 1CompletedPrimary
Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies
NCT02337842Phase 1WithdrawnPrimary
Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)
NCT00138476Phase 1CompletedPrimary
New Challenge Pool of Norwalk Virus Inoculum
Showing all 6 trials